Publicaciones más relevantes

Actualización de datos a 31/12/2023

A continuación se detallan las publicaciones más relevantes de 2023:

• Área de Cáncer.

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.

Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C.

Lancet Oncol. 2023 Aug.24(8):913-924.

PMID: 37414060

FI: 51,1

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.

Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano G.

Ann Oncol. 2023 Jun 01.

PMID: 37269905

FI: 50,5

Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.

Gonzalez Barca E, Tomás-Roca L, Esteve A, Rodriguez M, Gato L, Alonso-Alonso R, Martin Garcia-Sancho A, Cordoba R, Monter-Rovira A, Bastos-Oreiro M, Bergua Burgues JM, Sayas MJ, Viguria Alegria MC, Sanchez-Blanco JJ, Roig Pellicer M, Luzardo Henriquez HD, de Oña R, Cabezudo ME, Infante MS, Queizán Hernández JA, Sanz-Pamplona R, Blanco O, Mozos A, Climent F, Piris MA.

Am J Hematol. 2023 Jun.98(6):E134-E138.

PMID: 36882876

FI: 12,8

A complex microRNA regulatory network may control the HCP5/UTP3/c-Myc/VAMP3 signaling axis.

Cristóbal I, Santos A, Rojo F, García-Foncillas J.

Mol Ther. 2023 Apr 05.31(4):922-923.

PMID: 36933561

FI: 12,4

Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma.

Diez Valle R.

J Clin Oncol. 2023 Apr 10.41(11):1979-1981.

PMID: 36854064

FI: 45,4

• Área de Enfermedades Infecciosas, Inflamatorias y Crónicas.

European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma.

Papi A, Ferreira DS, Agache I, Baraldi E, Beasley R, Brusselle G, Coleman C, Gaga M, Gotera Rivera CM, Melén E, Pavord ID, Peñate Gómez D, Schuermans D, Spanevello A, Tonia T, Schleich F.

Eur Respir J. 2023 Oct.62(4).

PMID: 37678955

FI: 24,9

Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.

Nieto-Jiménez C, Sanvicente A, Díaz-Tejeiro C, Moreno V, Lopez de Sá A, Calvo E, Martínez-López J, Pérez-Segura P, Ocaña A.

Clin Transl Med. 2023 Sep.13(9):e1329.

PMID: 37740463

FI: 10,6

Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics.

Lorente-Sorolla C, Bernaola J, Sánchez-Mellado D, Gil-Martínez M, Naharro-González S, Betancor D, Fernández-Nieto M, Pinillos-Robles EJ, Santillán Coello JM, Villacampa-Aubá JM, Rodríguez-Nieto MJ, Sastre J, Valverde-Monge M, Rodrigo-Muñoz JM, Del Pozo V.

Allergy. 2023 Aug 29.

PMID: 37643083

FI: 12,4

MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction.

Medina JP, Bermejo-Álvarez I, Pérez-Baos S, Yáñez R, Fernández-García M, García-Olmo D, Mediero A, Herrero-Beaumont G, Largo R.

Front Immunol. 2023.14:1193179.

PMID: 37533852

FI: 7,3

Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.

Serrano-Villar S, Tincati C, Raju SC, Sáenz JS, Moreno E, Bargiela R, Cabello-Ubeda A, Sendagorta E, Kurz A, Perez Molina JA, de Benito A, Hov JR, Fernandez-Lopez L, Muriel A, Del Campo R, Moreno S, Trøseid M, Seifert J, Ferrer M.

Nat Med. 2023 Jul.29(7):1738-1749.

PMID: 37464040

FI: 82,9

• Área de Neurociencias.

The neural basis of somatosensory temporal discrimination threshold as a paradigm for time processing in the sub-second range: An updated review.

Ordás CM, Alonso-Frech F.

Neurosci Biobehav Rev. 2024 Jan.156:105486.

PMID: 38040074

FI: 8,2

Understanding the potential of digital therapies in implementing the standard of care for depression in Europe.

Courtet P, Amiot O, Baca-Garcia E, Bellardita L, Cerveri G, Clair AH, De Leo D, Drapier D, Fakra E, Gheysen F, Giner L, Gonzalez-Pinto A, Gussoni G, Haffen E, Lecardeur L, Mayoral-Cleries F, Mennini FS, Sáiz PA, Vieta E, Hidalgo DA, Volpe U.

Eur Psychiatry. 2023 Oct 24.66(1):e82.

PMID: 37872705

FI: 7,8

IF1 ablation prevents ATP synthase oligomerization, enhances mitochondrial ATP turnover and promotes an adenosine-mediated pro-inflammatory phenotype.

Domínguez-Zorita S, Romero-Carramiñana I, Santacatterina F, Esparza-Moltó PB, Simó C, Del-Arco A, Núñez de Arenas C, Saiz J, Barbas C, Cuezva JM.

Cell Death Dis. 2023 Jul 12.14(7):413.

PMID: 37433784

FI: 9

Text mining methods for the characterisation of suicidal thoughts and behaviour.

Sedano-Capdevila A, Toledo-Acosta M, Barrigon ML, Morales-González E, Torres-Moreno D, Martínez-Zaldivar B, Hermosillo-Valadez J, Baca-García E, MEmind Study Group (Segura-Valverde M, Hernando Merino E, Álvarez-García R, Puras-Rico P, Serrano-Marugán L).

Psychiatry Res. 2023 Apr.322:115090.

PMID: 36803841

FI: 11,3

Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

Toribio-Fernandez R, Ceron C, Tristão-Pereira C, Fernandez-Nueda I, Perez-Castillo A, Fernandez-Ferro J, Moro MA, Ibañez B, Fuster V, Cortes-Canteli M.

Br J Pharmacol. 2023 Jan 12.

PMID: 36633908

FI: 7,3

• Área de Enfermedades Renales, Metabólicas y Cardiovasculares.

Global Burden of Cardiovascular Diseases and Risks, 1990-2022.

Mensah GA, Fuster V, Murray CJL, Roth GA, Global Burden of Cardiovascular Diseases and Risks Collaborators (Ortiz A).

J Am Coll Cardiol. 2023 Dec 19.82(25):2350-2473.

PMID: 38092509

FI: 24,4

A mutual regulatory loop between miR-155 and SOCS1 influences renal inflammation and diabetic kidney disease.

Prieto I, Kavanagh M, Jimenez-Castilla L, Pardines M, Lazaro I, Herrero Del Real I, Flores-Muñoz M, Egido J, Lopez-Franco O, Gomez-Guerrero C.

Mol Ther Nucleic Acids. 2023 Dec 12.34:102041.

PMID: 37842165

FI: 8,8

Regulated cell death pathways in kidney disease.

Sanz AB, Sanchez-Niño MD, Ramos AM, Ortiz A.

Nat Rev Nephrol. 2023 May.19(5):281-299.

PMID: 36959481

FI: 41,5

Paradigm Shift: Cardiovascular Health in the Elderly-Beware of the Brain.

Fuster V, Turco JV, Cortes-Canteli M.

J Am Coll Cardiol. 2023 Mar 28.81(12):1214-1215.

PMID: 36948739

FI: 24,4

Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications.

Argente J, Dunkel L, Kaiser UB, Latronico AC, Lomniczi A, Soriano-Guillén L, Tena-Sempere M.

Lancet Diabetes Endocrinol. 2023 Mar.11(3):203-216.

PMID: 36620967

FI: 44,5

• Área de Genética y Genómica.

HLA-A*11:01 and HLA-C*04:01 are associated with severe COVID-19.

Castro-Santos P, Rojas-Martinez A, Riancho JA, Lapunzina P, Flores C, Carracedo Á, Díaz-Peña R; Scourge Cohort Group (Llanos L, Almoguera B, Ayuso C, Corton M, Mínguez P, Mahillo-Fernández I, Zazo S, Rojo F, Gadea I, Sarah Heili-Frades,Sanchez-Pernaute O).

HLA. 2023 Dec;102(6):731-739.

PMID: 37528566

FI: 8

A second update on mapping the human genetic architecture of COVID-19.

COVID-19 Host Genetics Initiative (Ayuso C).

Nature. 2023 Sep.621(7977):E7-E26.

PMID: 37674002

FI: 64,8

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

O'Mahony DG, Ramus SJ, Southey MC, Meagher NS, Hadjisavvas A, John EM, Hamann U, Imyanitov EN, Andrulis IL, Sharma P, Daly MB, Hake CR, Weitzel JN, Jakubowska A, Godwin AK, Arason A, Bane A, Simard J, Soucy P, Caligo MA, Mai PL, Claes KBM, Teixeira MR, Chung WK, Lazaro C, Hulick PJ, Toland AE, Pedersen IS, HEBON Investigators, Neuhausen SL, Vega A, de la Hoya M, Nevanlinna H, Dhawan M, Zampiga V, Danesi R, Varesco L, Gismondi V, Vellone VG, James PA, Janavicius R, Nikitina-Zake L, Nielsen FC, van Overeem Hansen T, Pejovic T, Borg A, Rantala J, Offit K, Montagna M, Nathanson KL, Domchek SM, Osorio A, García MJ, Karlan BY, GEMO Study Collaborators, De Fazio A, Bowtell D, AOCS Group, McGuffog L, Leslie G, Parsons MT, Dörk T, Speith LM, Dos Santos ES, da Costa AABA, Radice P, Peterlongo P, Papi L, Engel C, Hahnen E, Schmutzler RK, Wappenschmidt B, Easton DF, Tischkowitz M, Singer CF, Tan YY, Whittemore AS, Sieh W, Brenton JD, Yannoukakos D, Fostira F, Konstantopoulou I, Soukupova J, Vocka M, CZECANCA Consortium, Chenevix-Trench G, Pharoah PDP, Antoniou AC, Goldgar DE, Spurdle AB, Michailidou K, Consortium of Investigators of Modifiers of BRCA1/2, Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium.

Br J Cancer. 2023 Jun.128(12):2283-2294.

PMID: 37076566

FI: 8,8

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.

Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, McConkey GA, Zechner M, Klaric L, Griffiths F, Oosthuyzen W, Kousathanas A, Richmond A, Millar J, Russell CD, Malinauskas T, Thwaites R, Morrice K, Keating S, Maslove D, Nichol A, Semple MG, Knight J, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Begg C, Walsh T, Tenesa A, Flores C, Riancho JA, Rojas-Martinez A, Lapunzina P; GenOMICC Investigators; SCOURGE Consortium; ISARICC Investigators; 23andMe COVID-19 Team; Yang J, Ponting CP, Wilson JF, Vitart V, Abedalthagafi M, Luchessi AD, Parra EJ, Cruz R, Carracedo A, Fawkes A, Murphy L, Rowan K, Pereira AC, Law A, Fairfax B, Hendry SC, Baillie JK. (Llanos L, Ayuso C, Gadea I, Sarah Heili-Frades, Sanchez-Pernaute O).

Nature. 2023 May;617(7962):764-768.

PMID: 37198478

FI: 64,8

Prioritization of New Candidate Genes for Rare Genetic Diseases by a Disease-Aware Evaluation of Heterogeneous Molecular Networks.

de la Fuente L, Del Pozo-Valero M, Perea-Romero I, Blanco-Kelly F, Fernández-Caballero L, Cortón M, Ayuso C, Mínguez P.

Int J Mol Sci. 2023 Jan 14.24(2).

PMID: 36675175

FI: 5,6

• Área de Tecnología e Innovación Sanitaria.